CriticalSelective serotonin reuptake inhibitors (SSRIs)×First-generation antihistamine with anxiolytic activity
Updated · Methodology
Mechanism
Escitalopram causes dose-dependent QT prolongation. Post-marketing reports describe QT prolongation and ventricular arrhythmia, including torsade de pointes (escitalopram summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hydroxyzine is also associated with QT prolongation and torsade de pointes, mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine SmPC, AEMPS). The pair has not been studied specifically. Still, the escitalopram SmPC does not rule out an additive effect on the QT interval, and each Spanish SmPC lists the other drug among contraindicated combinations (escitalopram and hydroxyzine SmPCs, AEMPS). CYP2C19 is the main enzyme that metabolises escitalopram, and CYP2D6, which hydroxyzine inhibits, plays a smaller role. Alcohol dehydrogenase and CYP3A4/5 metabolise hydroxyzine, while CYP2D6, which escitalopram inhibits, does not (escitalopram and hydroxyzine SmPCs, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). Ventricular arrhythmias, including torsade de pointes, cause palpitations, dizziness and fainting. Both these arrhythmias and fainting appear among the adverse reactions of hydroxyzine (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After escitalopram was marketed, arrhythmias occurred mostly in women and in people with low potassium, a pre-existing long QT interval or other heart disease (escitalopram SmPC, AEMPS). Hydroxyzine itself causes drowsiness, headache, fatigue and dry mouth (hydroxyzine SmPC, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names escitalopram (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish escitalopram SmPC also contraindicates escitalopram with QT-prolonging drugs and names hydroxyzine in its list (escitalopram SmPC, AEMPS). The US hydroxyzine label only advises caution with QT-prolonging drugs (hydroxyzine label, US Food and Drug Administration, FDA); the Spanish SmPCs are stricter. Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Escitalopram is contraindicated in a history of long QT or congenital long QT syndrome (escitalopram SmPC, AEMPS). Before starting escitalopram, correct low potassium and magnesium and, in stable heart disease, consider an electrocardiogram (escitalopram SmPC, AEMPS). If hydroxyzine and escitalopram have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS), and stop escitalopram and record an electrocardiogram (escitalopram SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Escitalopram (nº registro 65230), sección 4.3 (2026)– AEMPS, CIMA, nº registro 65230 (Cipralex 10 mg, Lundbeck), revisión 03/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage